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Abstract
Insulin is a polypeptide hormone produced by the β cells present in Islets of Langerhans of the pancreas. Either 
failure to produce (type 1 diabetes) or utilize insulin (type 2 diabetes) causes diabetes mellitus. Insulin administration 
is used to treat type 1 diabetes. The common route for insulin administration is via subcutaneous injection. The oral 
insulin delivery has been proposed, however it suffers from poor bioavailability which is mainly due to the presence of 
proteolytic enzymes (pepsin, trypsin, and chymotrypsin) in the gastrointestinal (GI) tract. Protecting insulin from these 
enzymes when given orally might improve its bioavailability. In general, condensed tannins have been shown to reduce 
the activity of digestive enzymes. Epigallocatechin-3-gallate (EGCG) is the most abundant tannin component found 
in green tea. The present study investigated the ability of EGCG to protect insulin, through the formation of EGCG-
insulin complex, from the proteolytic enzyme action by pepsin and trypsin/chymotrypsin, in vitro. The amount of insulin 
remaining in the presence and absence of EGCG following incubation with either simulated gastric fluid (SGF) containing 
pepsin or simulated intestinal fluid (SIF) containing trypsin/chymotrypsin at two different temperatures (25°C and 37°C) 
for 1 hour and 7 hours was determined using an HPLC technique. The results showed that the presence of proteolytic 
enzymes (pepsin or trypsin/chymotrypsin) and absence of EGCG in the sample negatively affected the stability of insulin 
in solution. In the presence of EGCG, insulin was partially protected from trypsin/chymotrypsin but it was not protected 
from the action of pepsin. Insulin degradation was more pronounced at 37°C than that at 25°C (p = 0.0188). The initial 
concentration of insulin present (10 IU/mL or 20 IU/mL) or the time of incubation (1 h vs. 7 h) had no influence on the 
stability of insulin in the sample (p = 0.2842 and p = 0.2114, respectively). In conclusion, EGCG was not able to protect 
insulin against the proteolytic activity of pepsin. However, EGCG was shown to have some protective effect on insulin 
against the degradative effect of trypsin/chymotrypsin at room temperature, in vitro. Furthermore, this protection was 
greatly weakened at 37°C, which suggested that the protective action of EGCG would not be present in vivo. 
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Introduction
Diabetes mellitus is a disease characterized by disturbances in the 
regular metabolism of carbohydrates, proteins and fats. Glucose enters 
cells with the assistance of insulin, however in the case of diabetes 
mellitus the movement of glucose into the adipose and skeletal muscle 
cells is reduced and thereby results in the decreased levels of glycogen 
[1]. Insulin is a protein (polypeptide hormone) produced by the β 
cells of the pancreas and is chemically composed of two polypeptide 
chains connected through two intermolecular disulfide bridges. The 
two polypeptide chains are named chain A and chain B with 21 and 30 
amino acids respectively [2]. The free glucose circulating in the blood 
enters into the liver, muscles, and adipose tissues through insulin by 
stimulating the enzymatic reactions at the insulin receptors on the cell 
membrane. Membrane phosphorylation occurs by the stimulation 
of an intrinsic tyrosine kinase of the insulin receptor. It results in 
an enhancement of cell membrane permeability to glucose which 
involves some series of intracellular events [3]. Insulin is commonly 
administered in the form of subcutaneous injection, but there are 
several drawbacks associated with it, such as patient incompliance, 
local discomfort, and occasional hyper-insulinemia because of 
overdose [4,5]. Alternative routes of insulin delivery have been 
proposed such as per-oral (enteric-gastrointestinal) route, oral-buccal 
and sublingual routes, rectal delivery, ocular and intravaginal routes, 
transdermal delivery, intranasal delivery, and pulmonary route [6,7]. 
Although the majority of these non-invasive routes have not produced 
acceptable safety or efficacy profiles [7], such as the case with polymer-
encapsulated-insulin delivery [8], the nasal and oral routes remain the 
most promising for the insulin delivery [4]. 
Overall, the oral route is considered to be a patient-friendly mode 
of administration. However, protein administration suffers from 
poor bioavailability when given orally. Pharmaceutical scientists have 
adopted several strategies in order to improve on the bioavailability 
of orally administered insulin. Among these novel approaches 
were protecting insulin from the enzymatic degradation using anti-
proteolytic agents; penetration enhancers to increase gastrointestinal 
absorption of insulin; improving the stability of insulin by making 
some chemical modification to it; enhancing the contact of drugs 
with the mucus lining of the GI tract using the bio adhesive delivery 
systems; and using various carrier systems like nanoparticles and 
microspheres to improve the insulin bioavailability [4]. Oral insulin 
is easy to administer, has better patient compliance, has low index of 
intrusion which results in glycemic control, and also lowers the diabetic 
complications [9]. High porto-systemic gradient can be obtained by 
oral insulin because it is delivered from the GI tract to the liver. It 
mimics in that way the natural pathway for insulin handling by the 
body [10].
*Corresponding author: Antoine Al-Achi, Associate Professor, Department of 
Pharmaceutical Sciences, Campbell University College of Pharmacy and Health 
Sciences, P.O. Box 1090, Buies Creek, NC 27506, USA, Tel: 910-893-170; E-mail: 
alachi@campbell.edu 
Received June 29, 2015; Accepted July 16, 2015; Published July 22, 2015
Citation: Al-Achi A, Kota D (2015) Does Epigallocatechin-3-Gallate-Insulin Complex 
Protect Human Insulin from Proteolytic Enzyme Action? Clin Pharmacol Biopharm 
4: 139. doi:10.4172/2167-065X.1000139
Copyright: © 2015 Al-Achi A. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Citation: Al-Achi A, Kota D (2015) Does Epigallocatechin-3-Gallate-Insulin Complex Protect Human Insulin from Proteolytic Enzyme Action? Clin 
Pharmacol Biopharm 4: 139. doi:10.4172/2167-065X.1000139
Page 2 of 7
Volume 4 • Issue 3 • 1000139
Clin Pharmacol Biopharm
ISSN:  2167-065X CPB, an open access journal 
Tannins are the polyphenolic secondary metabolites obtained 
from the higher group of plants which can be either galloyl esters 
or their derivatives [11]. These are the complex organic and non-
nitrogenous plant products with astringent properties [12]. The 
studies conducted on experimental animals and on cell cultures using 
tannins have revealed that these compounds have various useful effects. 
According to these studies, it is believed that there are two different 
ways by which the tannins interact with proteins either by forming 
a non-absorbable complex structure or an absorbable complex with 
the proteins [13]. One of the important tannins known to man is 
Epigallocatechin-3-gallate (EGCG). It is a tannin component found 
in green tea (Camellia sinensis). In experimental animals, EGCG acted 
in a similar manner to insulin in reducing blood glucose in mammals 
through phosphorylation induction of insulin-sensitive residues on 
the transcription factor FOXO1a [14]. Previous studies have shown 
that the condensed tannins have decreased the activity of digestive 
enzymes obtained from various parts of rats and chicken intestinal 
tracts. Moreover, the activities of trypsin and α-amylase were reduced 
in various parts of the small intestine of rats after feeding them with 
the tannin-rich extracts obtained from different fodder plants [15] 
which may be associated with the ability of EGCG to bind with cross-
beta sheet aggregation intermediates of proteins [16]. Moreover, this 
inhibitory effect of EGCG on proteolytic enzymes (e.g., trypsin) was 
shown to be due to binding of EGCG to the enzymes through hydrogen 
bound formation [17], and this binding capability may be reversed by 
salivary proline-rich proteins [18]. Although EGCG had an inhibitory 
action on trypsin and chymotrypsin, it had no effect on the action of 
pepsin [18,19].  
EGCG was shown to be capable of binding to insulin by 
hydrophobic interactions and by the formation of hydrogen bounds 
[20,21]. The present study investigated the ability of EGCG to protect 
insulin, through the formation of EGCG-insulin complex, from the 
proteolytic enzyme action by pepsin and trypsin/chymotrypsin, in 
vitro. 
Methodology
Materials
Table 1 and Table 2 shows the list of materials and equipment used, 
respectively.
Methods
Ultraviolet (UV) spectrophotometry: Using a saturated solution 
of EGCG [the maximum solubility of EGCG in water is 25 mg per 1 
mL (0.055 M) at room temperature [6]], the detection wavelengths of 
EGCG were found to be at 206 nm and 274 nm.
High Performance Liquid Chromatography Method (HPLC) 
for human insulin: The parameters used on the HPLC system for 
the quantification of the human insulin are shown in Table 3. A high 
linear correlation was observed for the calibration curve (1 IU/mL to 
100 IU/mL; R2 = 0.9993; p < 0.0001). No interference with insulin peak 
was detected in the presence of proteolytic enzymes or EGCG. A peak 
for EGCG was also detected with the same HPLC conditions, except 
for using 274 nm as a detection wavelength. No interference with the 
insulin peak was observed when EGCG and/or proteolytic enzymes 
were present in solution (Table 3).
Determination of binding efficiency of EGCG and insulin: 
Insulin solutions (1 IU/mL to 40 IU/mL; 0.006 mmol/L to 0.24 mmol/L) 
were prepared in duplicate and mixed with an equal volume of EGCG 
solution (25 mg/mL; 0.055 M). The mixtures were kept undisturbed for 
Chemical Manufacturer
(−)- Epigallocatechin gallate (MW = 458.37 
Daltons) Sigma-Aldrich
Humulin-R (100 IU/mL)- Regular insulin human 
injection, USP (rDNA origin) [1 IU/mL = 0.0347 
mg/mL]
Eli-Lilly
Acetonitrile Fischer Scientific
Trifluoroacetic acid Fischer Scientific
Isopropyl alcohol EMD
Potassium phosphate monobasic Sigma Life Sciences
Sodium chloride Sigma-Aldrich
Porcine trypsin (1:250), Gamma Irradiated Sigma-Aldrich
Pepsin from porcine gastric mucosa (≥ 250 units/
mg solid) Sigma Life Sciences
α- chymotrypsin (EC 3.4.21.1, Type II: From 
bovine pancreas) Sigma Life Sciences
Sodium hydroxide Sigma-Aldrich
pH 7.00 buffer Contents: Orion 910107 ThermoElectron Corporation
pH 4.01 buffer Contents: Orion 910104 ThermoElectron Corporation
Hydrochloric acid (HCl) 12 N Sigma-Aldrich
Table 1: List of materials used.
Equipment and Model Manufacturer
Microbalance Sigma Life Sciences
UV-Vis spectrophotometer Agilent
Spectrophotometer cell (Cuvette) Capacity: 0.7 mL, 
10 mm light path VWR International
Micropipette Capacity: 5000 μL Gilson
Volumetric flasks Capacity: 5 mL, 10 mL, 25 mL, 
and 100 mL Pyrex
Transfer pipets (Disposable Polyethylene) Fischer Scientific
Vortex machine (Model: Genie 2) Fischer Scientific
HPLC clear shell vials w/plugs, Capacity: 1 mL VWR International
Centrifuge Sorvall Instruments
Centrifuge rotor Fixed angle: SS-34 05 20,000 rpm Sorvall Instruments
Weighing balance Model: AE163 Mettler
Micropipettes, Capacity: 10 μL, 20 μL, 100 μL, 1000 
μL, 5000 μL Gilson
Micropipette tips Capacity: 100 μL, 1000 μL Biohit 
HPLC (LC-10AD) Shimadzu
UV-Vis detector (Model:SPD-10A) Shimadzu
Degasser (DGV-14A) Shimadzu
Peak Simple Chromatography Data System (6 
channel USP port) SRI Instruments 
Autosampler Waters
C4 protein column Dimensions: 15 cm × 4.6 mm Vydac
Syringes (TB syringes, slip tip with Intradermal 
Bevel Needle) Capacity: 1 mL EXEL International 
Millex 0.22 μm Syringe-driven Filter Unit (PVDF 
filters) Millipore
pH meter (benchtop) Model: Orion 3 star Thermo Electron Corporation
Syringes, Capacity: 10 mL disposable, Model: 10 
mL Luer slip tip EXEL International
Table-2: List of equipment used.
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one hour at room temperature, to allow sufficient complex formation. 
After one hour incubation, the mixtures were centrifuged at a speed 
of 12,000 rpm for 20 minutes at 25°C. Following centrifugation, the 
supernatant was collected from each tube and was analyzed for insulin 
using HPLC. 
pH adjustment studies: The purpose of these experiments was to 
determine the volume of either 50% w/v NaOH or 12 N HCl needed 
to affect a change in pH of solution containing proteolytic enzymes 
for deactivating pepsin or trypsin/chymotrypsin, respectively. For 
proper proteolytic action, pepsin requires an acidic pH and trypsin/
chymotrypsin combination requires a neutral to basic pH. Thus, by 
changing the pH of the solution containing pepsin to a basic pH or that 
containing trypsin/chymotrypsin to an acidic pH would immediately 
halt the enzymatic action on insulin by the enzymes [23]. Simulated 
Gastric Fluid (SGF) was prepared by dissolving 0.0225 g of sodium 
chloride and 0.0332 g of pepsin in 7-mL of distilled water. To the 
mixture, 0.07 mL of 12 N HCl was added using a micropipette and the 
final volume was made to 10 mL using distilled water. The pH of the 
final solution was adjusted to 1.2 using 15 μL of 12N HCl. Simulated 
Intestinal Fluid (SIF) was prepared by dissolving 0.0679 g of monobasic 
potassium phosphate, 0.0509g of trypsin, and 0.0502 g of chymotrypsin 
in 1.9 mL of 0.2 N sodium hydroxide solution and the final volume was 
made to 10 mL using distilled water. The pH of the above solution was 
adjusted to 7.6 using 50% w/v NaOH solution. Solutions containing 
EGCG-insulin (10 IU/mL or 20 IU/mL; 0.06 mmol/L or 0.12 mmol/L) 
in the presence of SGF or SIF (Test Group) were treated with 50% w/v 
NaOH or 12 N HCl, respectively in order to halt the degradative action 
of the enzymes on insulin. In addition solutions containing only insulin 
(10 IU/mL or 20 IU/mL) with SGF or SIF (Control I) or only EGCG 
(0.055 M) with SGF or SIF (Control II) were also adjusted to basic pH 
or acidic pH with 50% NaOH or 12 N HCl, respectively. Samples were 
treated for either 1 h or 7 h under aforementioned conditions prior to 
adding the 50% NaOH or 12 N HCl. The volume of 50% w/v NaOH 
and 12 N HCl needed to affect this change in pH were recorded (Table 
4, Table 5). For all the samples prepared, the concentration units listed 
for the various components reflected those found prior to mixing with 
SGF or SIF solutions. SGF and SIF solutions were mixed with solutions 
containing only insulin, only EGCG, or only EGCG-insulin complex 
in a ratio of 1:2 (v/v) (sample:SGF or sample:SIF) (actual volumes were 
100 µL of sample mixed with 200 µL of proteolytic enzyme solution).
Effect of proteolytic enzymes on the stability of insulin in the 
presence and absence of aqueous EGCG solution: An experiment 
was conducted to determine the effect of proteolytic enzymes on the 
stability of insulin in the presence (0.055 M) and absence of EGCG 
solution. Solutions containing EGCG-insulin (10 IU/mL or 20 IU/
mL; 0.06 mmol/L or 0.12 mmol/L) in the presence of SGF or SIF (Test 
Group) and solutions containing only insulin (10 IU/mL or 20 IU/
mL) with SGF or SIF (Control I) or only EGCG (0.055 M) with SGF 
or SIF (Control II) were prepared (Control II samples were used to 
ascertain that the conditions of incubation used did not interfere with 
the insulin peak on HPLC assay. As stated above, no interference with 
the insulin peak was observed when EGCG and/or proteolytic enzymes 
were present in solution). Samples were treated for either 1 h or 7 h in 
triplicates and kept under 25°C or 37°C (insulin was stable under those 
conditions if proteolytic enzymes were not added to solution). After 
pH adjustment to halt the action of proteolytic enzymes on insulin 
degradation as specified above, the samples were filtered and analyzed 
on HPLC for their content of insulin. For all the samples prepared, the 
concentration units listed for the various components reflected those 
found prior to mixing with SGF or SIF solutions. SGF and SIF solutions 
were mixed with solutions containing only insulin, only EGCG, or only 
EGCG-insulin complex in a ratio of 1:2 (v/v) (sample: SGF or sample: 
SIF) (actual volumes were 100 µL of sample mixed with 200 µL of 
proteolytic enzyme solution).
Statistical analysis: JMP Statistical Discovery Software (SAS 
Institute, Cary, NC) was used for the statistical analysis. A multifactorial 
analysis of variance method (MANOVA) was used to test the difference 
in insulin content (the dependent variable) remaining following the 
treatment with the enzymes in the presence of EGCG. The independent 
variables were the initial concentration of insulin present (10 IU/mL 
and 20 IU/mL), temperature (25°C and 37°C), and time of exposure 
to enzymes (1 h and 7 h). A p value of less than 5% was considered 
significant. 
Results
The percentage of insulin bound to ECGC following incubation at 
25°C for 1 hour is shown in Figure 1. 
The volume (µL) of 50% NaOH or 12 N HCl needed to affect a 
change in pH are shown in Table 4 and Table 5, respectively. The 
effect of proteolytic enzymes on insulin (10 IU/mL or 20 IU/mL; 0.06 
mmol/L or 0.12 mmol/L) degradation in the presence or absence of 
ECGC (25 mg/mL; 0.055 M) at different temperatures (25°C and 37°C) 
for 1 h or 7 h incubation periods is shown in Figure 2. 
Discussion
For the initial concentrations of insulin used in this study (1 IU/
mL to 40 IU/mL; 0.006 mmol/L to 0.24 mmol/L), almost all the insulin 
present in solution formed a complex with EGCG (mean ± S.D. 95.9% 
±  5.6%; n = 12; 95% CI = 92.3% - 99.5%) (Figure 1) Wang et al. [24] have 
shown that EGCG directly bound to insulin primarily via hydrogen 
bond formation, and that the binding was independent of pH and 
temperature. In addition to hydrogen bound formation, EGCG-insulin 
complex was also held together by hydrophobic interactions [20,21]. 
The hydrogen bounds were expected to form between the hydroxyl 
groups of EGCG and certain currently undefined amino acid residues 
on insulin chain [18]. Insulin was quickly and completely degraded 
by SGF (pepsin) with or without EGCG being present in the solution 
(Figure 2). This agrees with the results obtained from a previous study 
where the proteolytic action of pepsin (SGF) on free insulin was 
completed within one minute of incubation with the enzyme [2]. Also, 
EGCG was shown to be unable to halt the enzymatic activity of pepsin, 
and in some cases even enhanced the proteolytic action of pepsin 
Parameter Value
Injection Volume 15 μL
Flow Rate 2.0 mL/min
Wavelength 215 nm
Run Time 20 minutes
Column Vydac C4 protein column (15 cm × 4.6 mm)
      Mobile phase
Component A Acetonitrile (10-60%) with 0.05% Trifluoroacetic acid
Component B Water (90-40%) with 0.05% Trifluoroacetic acid
Method used Gradient elution
Table-3: HPLC parameters for the quantification of insulin.
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[19]. Naz et al. [18] have shown that EGCG inhibited several digestive 
enzymes in the following descending order -amylase > chymotrypsin 
> trypsin > lactase; negligible or no inhibition of pepsin by EGCG was 
noted in these experiments. 
The destruction of free insulin by trypsin/chymotrypsin (SIF) in 
the absence of an enzyme inhibitor was found to follow a first-order 
type reaction with a first-order degradation rate constant of 0.069 
min-1 at 37°C, in vitro [23]. A multifactorial analysis of variance test 
(MANOVA) was performed on the data obtained from the insulin 
degradation experiments with SIF (trypsin/chymotrypsin) and in the 
presence of EGCG-insulin complex. [In the absence of EGCG, all of 
the insulin was degraded by trypsin/chymotrypsin (Figure 2)].  Based 
on the analysis of the results (Figure 2), the temperature was the only 
factor that significantly (p = 0.0188) affected the amount of insulin 
remaining in solution following treatment with trypsin/chymotrypsin 
(Figure 3).
The effect of the proteolytic enzymes on insulin was halted at the 
end of the experiment [23] by changing the pH of the sample from 
(average ± S.D.; n = 20) 2.58 ± 0.62 to 8.06 ± 0.57 in the case of pepsin, 
and from 7.64 ± 0.48 to 1.47  0.73 for trypsin/chymotrypsin samples 
(Tables 4 and 5). Under those pH conditions, free insulin existed as a 
monomer (pH ∼ 2.0) or as a dimer (pH ∼ 7.4) in solution. Moreover, 
the presence of EGCG in solutions containing insulin was shown to 
prevent insulin aggregation to some extent; this aggregation prevention 
reached its maximum point at insulin concentration in the range of 
0.1-0.2 mmol/L [24] (in the present study, the insulin concentration 
was 0.06 mmol/L or 0.12 mmol/L). Samples containing EGCG-insulin 
Figure-1: Percentage of insulin bound to EGCG (25 mg/mL) at room 
temperature following one hour incubation. Insulin solutions (1 IU/mL to 40 
IU/mL; 0.006 mmol/L to 0.24 mmol/L) were prepared in duplicate and mixed 
with an equal volume of EGCG solution (25 mg/mL; 0.055 M). Each error bar 
is constructed using one standard deviation from the mean.
S.No Conc. of Insulin added (IU/mL) Sample
Proteolytic 
enzymes added
Incubation period 
(h) Temperature (
°C) Initial pH Volume of 50% w/v NaOH added (μL) Final pH
1 10
Control I 
(10 IU/mL)                 
SGF 1 25 1.77 3 8.12
2 10 SGF 7 25 2.20 2 8.64
3 10 SGF 1 37 1.67 2 7.86
4 10 SGF 7 37 2.60 2 7.62
5 0
Control II 
(EGCG 0.055 M)    
        
SGF 1 25 2.60 2 7.91
6 0 SGF 7 25 2.63 2 8.62
7 0 SGF 1 37 2.52 2 9.82
8 0 SGF 7 37 3.24 2 8.12
9 10
Test group
(EGCG-insulin 
complex)
SGF 1 25 2.56 2 7.47
10 10 SGF 7 25 2.33 2 7.71
11 10 SGF 1 37 2.91 2 7.96
12 10 SGF 7 37 2.39 2 7.42
13 20
Control I 
(20 IU/mL)                   
SGF 1 25 2.45 2 7.57
14 20 SGF 7 25 2.41 2 8.04
15 20 SGF 1 37 2.03 2 8.24
16 20 SGF 7 37 4.72 2 7.62
17 20
Test group
(EGCG-insulin 
complex)                      
SGF 1 25 2.69 2 7.44
18 20 SGF 7 25 2.82 2 8.64
19 20 SGF 1 37 2.60 3 8.06
20 20 SGF 7 37 2.39 4 8.34
Average ± SD 2.58 ± 0.62 2.2 ± 0.5 µL 8.06 ± 0.57
Table-4: Volumes of 50% w/v NaOH used for pH adjustment of the samples.
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S.No Conc. of Insulin added (IU/mL) Sample
Proteolytic 
enzymes
Incubation period 
(h) Temperature (
°C) Initial pH Volume of 12 N HCl added (μL) Final pH
1 10
Control I 
(10 IU/mL)                 
SIF 1 25 6.81 2 1.54
2 10 SIF 7 25 7.48 6 1.40
3 10 SIF 1 37 7.06 2 1.54
4 10 SIF 7 37 7.85 9 1.28
5 0
Control II 
(EGCG 0.055 M)    
SIF 1 25 8.08 6 1.22
6 0 SIF 7 25 8.12 6 1.24
7 0 SIF 1 37 8.61 6 1.25
8 0 SIF 7 37 7.74 7 1.22
9 10
Test group
(EGCG-insulin 
complex)                      
SIF 1 25 7.92 8 1.45
10 10 SIF 7 25 6.68 7 1.24
11 10 SIF 1 37 8.22 6 1.28
12 10 SIF 7 37 7.62 6 1.24
13 20
Control I
(20 IU/mL)                 
SIF 1 25 8.12 6 1.32
14 20 SIF 7 25 7.58 5 1.28
15 20 SIF 1 37 7.52 5 1.30
16 20 SIF 7 37 7.52 4 1.33
17 20
Test group
(EGCG-insulin 
complex)                      
SIF 1 25 7.70 8 1.31
18 20 SIF 7 25 7.07 5 1.25
19 20 SIF 1 37 7.56 5 1.36
20 20 SIF 7 37 7.49 3 1.25
Average ± SD 7.64 ± 0.48 5.6 ± 1.8 µL 1.47 ± 0.73
Table-5: Volumes of 12 N HCl used for pH adjustment of the samples.
Figure-2: Percentage of insulin remaining after treatment with proteolytic enzymes (SGF = pepsin; SIF = trypsin/chymotrypsin) incubated at either 25°C or 37°C 
for 1 h or 7 h in the presence or absence of EGCG (25 mg/mL; 0.055 M). Initial concentration of insulin was 10 IU/mL or 20 IU/mL (0.06 mmol/L or 0.12 mmol/L). 
Each error bar was constructed using 1 standard error from the mean (n=6).
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Figure-4: Profiler for the input factors and their collective effects on the outcome: Proteolytic enzyme = SIF (trypsin/chymotrypsin), incubation time = 7 hours, 
temperature = 37°C, and initial concentration of insulin = 20 IU/mL. Given these conditions, the predicted percentage of insulin remaining was 30.56% [95% CI = 
-8.62% to 69.75%].
Figure-3: Profiler for the input factors and their values to produce a maximized value (by maximizing the desirability function) in the outcome: Proteolytic enzyme = 
SIF (trypsin/chymotrypsin), incubation time = 1 or 7 hours (p = 0.2114), temperature = 25°C or 37°C (p = 0.0188), and initial concentration of insulin = 10 or 20 IU/mL 
(p = 0.2842). Given incubation time of 7 hours, a temperature of 25°C, and an initial concentration of insulin of 20 IU/mL, the predicted percentage of insulin remaining 
was 103.86% (95% CI = 64.68% to 143.05%).
complex and treated with trypsin/chymotrypsin had more pronounced 
Insulin degradation at 37°C than that at 25°C (p = 0.0188). On the 
other hand, the initial concentration of insulin present (10 IU/mL or 
20 IU/mL) or the time of incubation (1 h vs. 7 h) had no influence 
on the stability of insulin in the sample (p = 0.2842 and p = 0.3012, 
respectively) (Figure-3). EGCG demonstrated no protective action 
on insulin in the presence of pepsin (SGF) under the experimental 
conditions, while it protected insulin to a certain degree when the 
hormone was incubated with SIF (trypsin/chymotrypsin) (Figure-2). 
This perhaps was due to the difference between pepsin and trypsin/
chymotrypsin action on insulin. Human insulin is composed of 51 
amino acids forming two chains (A and B). Disulfide bonds link the 
two chains together at specific locations [25]. Trypsin cleaves insulin 
at the following locations B29-Lys and B22-Arg, while chymotrypsin 
attacks insulin at locations A11-Cys, A14-Tyr, A19-Tyr, B1-Phe, B15-
Leu, B16-Tyr, B25-Phe, and B26-Tyr [26] Insulin chains are much 
more susceptible to the attack by pepsin as the enzyme is capable to 
cleave the chain at 15 locations (four sites in the region of A13-A19, 
five spots in A2-A8 segment, and six positions located in the B chain) 
[26]. Since pepsin action was fast and complete in degrading insulin 
held within the EGCG-insulin complex, this could point out to the 
fact that the hydrogen bound formation and hydrophobic interactions 
between insulin and EGCG were not sufficient enough to shield the 
aforementioned vulnerable sites available on insulin chain from the 
proteolytic action of pepsin, keeping some or all of these sites exposed 
to the damaging effect of the enzyme. On the other hand, the protective 
effect of EGCG on insulin seen with SIF was perhaps related in part to 
the EGCG-insulin complex’s three-dimensional structure formation in 
protecting to some degree the 10 susceptible sites from the degradative 
action of trypsin (two locations) and chymotrypsin (eight locations). 
Analysis of data indicated that EGCG-insulin complex could resist 
the proteolytic degradation imposed by trypsin/chymotrypsin for a 
period of 7 hours with a concentration of insulin in solution of 20 IU/
mL and stored at room temperature (Figure 3). However, a change in 
temperature from 25°C to 37°C would cause almost a total destruction of 
insulin, present in the solution in the form of EGCG-insulin complex, 
by trypsin/chymotrypsin (predicted insulin remaining = 30.56%; 95% 
CI = -8.62% to 69.75%) (Figure 4). 
Thus, EGCG-insulin complex’s degradation by trypsin/
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chymotrypsin appears to be highly sensitive to a rise in temperature. 
One explanation to that might be that the vulnerable sites on insulin 
chain that were normally susceptible to trypsin/chymotrypsin action 
and were originally shielded by EGCG-insulin complex formation 
became exposed to the enzymes at higher temperatures (37°C). Perhaps 
this was related to hydrogen bounds weakening as the temperature 
increased from 25°C to 37°C [27]. Further investigations are needed 
to ascertain this temperature-dependent sensitivity of the complex 
to its denaturation by the enzymes. The implication of this study 
is that although insulin could form a complex with EGCG at room 
temperature, shielding its susceptible sites from trypsin/chymotrypsin 
proteolytic action, this protection lessened greatly and perhaps totally 
disappeared, at 37°C. Thus, the oral administration of EGCG-insulin 
complex in a form of enteric coated delivery system (to protect 
insulin from the action of pepsin) would not be expected to render 
any improvement in insulin bioavailability over that seen with insulin 
alone. Furthermore, any freed EGCG from the complex would not be 
expected to have a significant inhibitory activity on the enzymes (i.e., 
trypsin and chymotrypsin) in vivo because of the presence of salivary 
proline-rich proteins would protect the digestive enzymes from EGCG 
inhibitory effect [18]. From all practical points of view, EGCG cannot 
be expected to protect insulin administered orally from the degradative 
proteolytic action presents in the GI track.
Conclusions
In summary, the complex formation between EGCG and insulin 
did not protect insulin from the proteolytic action of pepsin, while 
EGCG-insulin complex rendered the degradative activity of trypsin 
and chymotrypsin on insulin less pronounced at room temperature. 
The stability of insulin in solution as EGCG-insulin complex in the 
presence of trypsin/chymotrypsin was found to be temperature-
dependent. EGCG did not protect insulin from the action of proteolytic 
enzymes at 37°C, the one expected to be encountered in vivo. 
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